Computer simulations show higher benefit of lecanemab in males compared to females

Computational simulations using data from a Phase 3 trial of a potential new medication that may slow cognitive decline for people living with Alzheimer’s disease, lecanemab, showed that this medication is effective in males but also suggested no or limited effectiveness in females.

 

From: Andrews, D., Ducharme, S., Chertkow, H., Sormani, M.P., Collins, D.L. (2025) The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect. Alzheimer’s & Dementia; 21:e14467

Share

Published on April 16, 2025

CCNA - CCNV white logo

Receive the
latest news

Stay updated with the latest research developments from CCNA-CCNV. Our news section provides insights into cutting-edge studies, advancements in dementia care, and key findings in brain health research.

Illustration of elderly people on a park bench

You might be interested in...

  • August 6, 2025

    Eden Mancor wins poster award at AAIC!

  • July 30, 2025

    CIHR’s CCNA Phase III: Research Teams funding announcement

  • July 23, 2025

    Launch of a new website for the Indigenous Cognitive Health Program